Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Drilon

Showing results (31-40 of 268) with videos related to

Pageof 27
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 7, 2024
Reply to Comment on "Brief Report: Tyrosine Kinase Inhibitors for Lung Cancers That Inhibit MATE-1 Can Lead to 'False' Decreases in Renal Function"Monica F Chen, Clare Wilhelm, Alexander Drilon, et al.
Cancer Cell|January 12, 2021
The NCI-MATCH: A National, Collaborative Precision Oncology Trial for Diverse Tumor HistologiesYonina R Murciano-Goroff, Alexander Drilon, Zsofia K Stadler
Expert Review of Anticancer Therapy|November 22, 2015
Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancerThu Oanh Dang, Adebayo Ogunniyi, Meagan S Barbee, et al.
Nature Reviews. Clinical Oncology|September 1, 2017
Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistanceAlison M Schram, Matthew T Chang, Philip Jonsson, et al.
Therapeutics and Clinical Risk Management|July 28, 2018
Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of <i>NTRK</i>, <i>ROS1</i>, and <i>ALK</i> fusion-positive solid tumorsDazhi Liu, Michael Offin, Stephen Harnicar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2020
State-of-the-Art Strategies for Targeting <i>RET</i>-Dependent CancersVivek Subbiah, Dong Yang, Vamsidhar Velcheti, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 31, 2016
Targeting MET in Lung Cancer: Will Expectations Finally Be MET?Alexander Drilon, Federico Cappuzzo, Sai-Hong Ignatius Ou, et al.
Cancer Discovery|June 3, 2024
Optimus-Era Dose Finding for Rare CancersYonina R Murciano-Goroff, Sean M Devlin, Alexia Iasonos, et al.
Cancer|September 5, 2020
The METeoric rise of MET in lung cancerAlex Friedlaender, Alexander Drilon, Giuseppe Luigi Banna, et al.
Cancer Discovery|December 12, 2023
Precision Oncology: 2023 in ReviewYonina R Murciano-Goroff, Sarah P Suehnholz, Alexander Drilon, et al.
Pageof 27

Showing results (31-40 of 268) with videos related to

Sort By:
Pageof 27
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 7, 2024
Reply to Comment on "Brief Report: Tyrosine Kinase Inhibitors for Lung Cancers That Inhibit MATE-1 Can Lead to 'False' Decreases in Renal Function"Monica F Chen, Clare Wilhelm, Alexander Drilon, et al.
Cancer Cell|January 12, 2021
The NCI-MATCH: A National, Collaborative Precision Oncology Trial for Diverse Tumor HistologiesYonina R Murciano-Goroff, Alexander Drilon, Zsofia K Stadler
Expert Review of Anticancer Therapy|November 22, 2015
Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancerThu Oanh Dang, Adebayo Ogunniyi, Meagan S Barbee, et al.
Nature Reviews. Clinical Oncology|September 1, 2017
Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistanceAlison M Schram, Matthew T Chang, Philip Jonsson, et al.
Therapeutics and Clinical Risk Management|July 28, 2018
Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of <i>NTRK</i>, <i>ROS1</i>, and <i>ALK</i> fusion-positive solid tumorsDazhi Liu, Michael Offin, Stephen Harnicar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2020
State-of-the-Art Strategies for Targeting <i>RET</i>-Dependent CancersVivek Subbiah, Dong Yang, Vamsidhar Velcheti, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 31, 2016
Targeting MET in Lung Cancer: Will Expectations Finally Be MET?Alexander Drilon, Federico Cappuzzo, Sai-Hong Ignatius Ou, et al.
Cancer Discovery|June 3, 2024
Optimus-Era Dose Finding for Rare CancersYonina R Murciano-Goroff, Sean M Devlin, Alexia Iasonos, et al.
Cancer|September 5, 2020
The METeoric rise of MET in lung cancerAlex Friedlaender, Alexander Drilon, Giuseppe Luigi Banna, et al.
Cancer Discovery|December 12, 2023
Precision Oncology: 2023 in ReviewYonina R Murciano-Goroff, Sarah P Suehnholz, Alexander Drilon, et al.
Pageof 27